Fragment-based whole cell screen delivers hits against M. tuberculosis and non-tuberculous mycobacteria

Frontiers in Microbiology

Volumn 7, Issue SEP, 2016, Pages

  Moreira, Wilfried ^a   Lim, Jia Jie ^a   Yeo, Si Ying ^a   Ramanujulu, Pondy M ^b   Dymock, Brian W ^b   Dick, Thomas ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Fragments; M. abscessus; M. avium; NTM; Poly pharmacology; Tuberculosis

Indexed keywords

ANTIMYCOBACTERIAL AGENT; ANTIMYCOBACTERIAL FRAGMENT DRUG; COLISTIN; FLUCONAZOLE; UNCLASSIFIED DRUG; VANCOMYCIN;

ARTICLE; ATYPICAL MYCOBACTERIUM; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; CANDIDA ALBICANS; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; CYTOTOXICITY; DRUG DESIGN; DRUG SCREENING; DRUG SELECTIVITY; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR LIBRARY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; TUBERCULOSIS;

EID: 84992741070     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2016.01392     Document Type: Article

References (27)

1. Aksamit, T. R., Philley, J. V., and Griffith, D. E. (2014). Nontuberculous mycobacterial (NTM) lung disease: the top ten essentials. Respir. Med. 108, 417-425. doi: 10.1016/j.rmed.2013.09.014
2. Barry, C. E. III, Boshoff, H. I., Dartois, V., Dick, T., Ehrt, S., Flynn, J., et al. (2009). The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 7, 845-855. doi: 10.1038/nrmicro2236
3. Baurin, N., Aboul-Ela, F., Barril, X., Davis, B., Drysdale, M., Dymock, B., et al. (2004). Design and characterization of libraries of molecular fragments for use in NMR screening against protein targets. J. Chem. Inf. Comput. Sci. 44, 2157-2166. doi: 10.1021/ci049806z
4. Campbell, J. (2011). High-throughput assessment of bacterial growth inhibition by optical density measurements. Curr. Protoc. Chem. Biol. 3:100115
5. Congreve, M., Carr, R., Murray, C., and Jhoti, H. (2003). A 'rule of three' for fragment-based lead discovery? Drug Discov. Today 8, 876-877. doi: 10.1016/S1359-6446(03)02831-9
6. Dartois, V. (2014). The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat. Rev. Microbiol. 12, 159-167. doi: 10.1038/nrmicro3200
7. Dartois, V., and Barry, C. E. (2010). Clinical pharmacology and lesion penetrating properties of second-and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis. Curr. Clin. Pharmacol. 5, 96-114. doi: 10.2174/157488410791110797
8. Dartois, V., and Barry, C. E. III. (2013). A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis. Bioorg. Med. Chem. Lett. 23, 4741-4750. doi: 10.1016/j.bmcl.2013.07.006
9. Dausset, J., and Contu, L. (1967). Drug-induced hemolysis. Annu. Rev. Med. 18, 55-70. doi: 10.1146/annurev.me.18.020167.000415
10. Dick, T., Dartois, V., Keller, T., and Matter, A. (2007). "TB drug discovery from target identification to proof of concept studies, "in Handbook of Tuberculosis: Clinics, Diagnostics, Therapy and Epidemiology, eds S. H. E. Kaufmann and P. van Helden (Weinheim: Wiley-VCH), 139-159.
11. Ertl, P., Rohde, B., and Selzer, P. (2000). Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J. Med. Chem. 43, 3714-3717. doi: 10.1021/jm000942e
12. Gopal, P., and Dick, T. (2014). Reactive dirty fragments: implications for tuberculosis drug discovery. Curr. Opin. Microbiol. 21, 7-12. doi: 10.1016/j.mib.2014.06.015
13. Gopal, P., and Dick, T. (2015). The new tuberculosis drug Perchlozone� shows cross-resistance with thiacetazone. Int. J. Antimicrob. Agents 45, 430-433. doi: 10.1016/j.ijantimicag.2014.12.026
14. Griffith, D. E. (2011). The talking Mycobacterium abscessus blues. Clin. Infect. Dis. 52, 572-574. doi: 10.1093/cid/ciq252
15. Griffith, D. E., Aksamit, T., Brown-Elliott, B. A., Catanzaro, A., Daley, C., Gordin, F., et al. (2007). An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 175, 367-416. doi: 10.1164/rccm.200604-571ST
16. Gwynn, M. N., Portnoy, A., Rittenhouse, S. F., and Payne, D. J. (2010). Challenges of antibacterial discovery revisited. Ann. N. Y. Acad. Sci. 1213, 5-19. doi: 10.1111/j.1749-6632.2010.05828.x
17. Hopkins, A. L., Keseru, G. M., Leeson, P. D., Rees, D. C., and Reynolds, C. H. (2014). The role of ligand efficiency metrics in drug discovery. Nat. Rev. Drug Discov. 13, 105-121. doi: 10.1038/nrd4163
18. Lakshminarayana, S. B., Huat, T. B., Ho, P. C., Manjunatha, U. H., Dartois, V., Dick, T., et al. (2015). Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents. J. Antimicrob. Chemother. 70, 857-867. doi: 10.1093/jac/dku457
19. Lipinski, C. A. (2000). Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44, 235-249. doi: 10.1016/S1056-8719(00)00107-6
20. Murugasu-Oei, B., and Dick, T. (2000). Bactericidal activity of nitrofurans against growing and dormant Mycobacterium bovis BCG. J. Antimicrob. Chemother. 46, 917-919. doi: 10.1093/jac/46.6.917
21. Nessar, R., Cambau, E., Reyrat, J. M., Murray, A., and Gicquel, B. (2012). Mycobacterium abscessus: a new antibiotic nightmare. J. Antimicrob. Chemother. 67, 810-818. doi: 10.1093/jac/dkr578
22. Park, I. K., and Olivier, K. N. (2015). Nontuberculous mycobacteria in cystic fibrosis and non-cystic fibrosis bronchiectasis. Semin. Respir. Crit. Care Med. 36, 217-224. doi: 10.1055/s-0035-1546751
23. Payne, D. J., Gwynn, M. N., Holmes, D. J., and Pompliano, D. L. (2007). Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29-40. doi: 10.1038/nrd2201
24. Riss, T. L., Moravec, R. A., Niles, A. L., Benink, H. A., Worzella, T. J., Minor, L., et al. (2004). "Cell viability assays, "in Assay Guidance Manual, eds G. S. Sittampalam, N. P. Coussens, H. Nelson, M. Arkin, D. Auld, C. Austin, et al. (Rockville, MD: Bethesda).
25. Scott, D. E., Coyne, A. G., Hudson, S. A., and Abell, C. (2012). Fragment-based approaches in drug discovery and chemical biology. Biochemistry 51, 4990-5003. doi: 10.1021/bi3005126
26. Via, L. E., Savic, R., Weiner, D. M., Zimmerman, M. D., Prideaux, B., Irwin, S. M., et al. (2015). Host-mediated bioactivation of pyrazinamide: implications for efficacy, resistance, and therapeutic alternatives. ACS Infect. Dis. 1, 203-214. doi: 10.1021/id500028m
27. WHO (2015). Global Tuberculosis Report 2015. Geneva: World Health Organization.